Results 11 to 20 of about 211,957 (166)

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Haematologica, 2012
Background In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B ...
Hongtao Liu, Jeffrey L. Johnson, Greg Koval, Greg Malnassy, Dorie Sher, Lloyd E. Damon, Eric D. Hsi, Donna Marie Bucci, Charles A. Linker, Bruce D. Cheson, Wendy Stock   +10 more
doaj   +1 more source

Liquid biopsies and minimal residual disease in lymphoid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and ...
Maroun Bou Zerdan, Joseph Kassab, Ludovic Saba, Elio Haroun, Morgan Bou Zerdan, Sabine Allam, Lewis Nasr, Walid Macaron, Mahinbanu Mammadli, Sarah Abou Moussa, Chakra P. Chaulagain   +10 more
doaj   +1 more source

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

Haematologica, 2019
Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies ...
Brian Ball, Eytan M. Stein
doaj   +1 more source

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Haematologica, 2017
Our aim was to improve outcome prediction after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by combining cytogenetic and molecular data at diagnosis with minimal residual disease assessment by multicolor flow-cytometry at
Betül Oran, Jeff L. Jorgensen, David Marin, Sa Wang, Sairah Ahmed, Amin M. Alousi, Borje S. Andersson, Qaiser Bashir, Roland Bassett, Genevieve Lyons, Julianne Chen, Katy Rezvani, Uday Popat, Partow Kebriaei, Keyur Patel, Gabriela Rondon, Elizabeth J. Shpall, Richard E. Champlin   +17 more
doaj   +1 more source

Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia

Haematologica, 2010
Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute ...
Izaskun Elorza, Carlos Palacio, Jose Luis Dapena, Laura Gallur, José Sánchez de Toledo, Cristina Díaz de Heredia   +5 more
doaj   +1 more source

Liquid biopsies and minimal residual disease in myeloid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies.
Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, Chakra P. Chaulagain   +9 more
doaj   +1 more source

Dynamics of Minimal Residual Disease in Neuroblastoma Patients

Frontiers in Oncology, 2019
Neuroblastoma is a common extracranial solid tumor of neural crest (NC) origin that accounts for up to 15% of all pediatric cancer deaths. The disease arises from a transient population of NC cells that undergo an epithelial-mesenchymal transition (EMT ...
Suguru Uemura, Toshiaki Ishida, Khin Kyae Mon Thwin, Nobuyuki Yamamoto, Akihiro Tamura, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Kyaw San Lin, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima, Noriyuki Nishimura   +13 more
doaj   +1 more source

Cancer Special Issue: Early detection and minimal residual disease.

PLoS Medicine, 2021
Beryne Odeny discusses PLOS Medicine's Special Issue on early cancer detection and minimal residual disease.
Beryne Odeny
doaj   +1 more source

Cellular dormancy in minimal residual disease following targeted therapy

Breast Cancer Research, 2021
Background Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades.
Jason R. Ruth, Dhruv K. Pant, Tien-chi Pan, Hans E. Seidel, Sanjeethan C. Baksh, Blaine A. Keister, Rita Singh, Christopher J. Sterner, Suzanne J. Bakewell, Susan E. Moody, George K. Belka, Lewis A. Chodosh   +11 more
doaj   +1 more source

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

Haematologica, 2016
Quantification of minimal residual disease may guide therapeutic strategies in mantle cell lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard method for minimal residual disease analysis is real-time quantitative ...
Morgane Cheminant, Coralie Derrieux, Aurore Touzart, Stéphanie Schmit, Adrien Grenier, Amélie Trinquand, Marie-Hélène Delfau-Larue, Ludovic Lhermitte, Catherine Thieblemont, Vincent Ribrag, Stéphane Cheze, Laurence Sanhes, Fabrice Jardin, François Lefrère, Richard Delarue, Eva Hoster, Martin Dreyling, Vahid Asnafi, Olivier Hermine, Elizabeth Macintyre   +19 more
doaj   +1 more source